Drug intelligence / Profile preview

MRx0518 + pembrolizumab

Development stage: Unknown
Lead developer: 4D pharma
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

MRx0518 + pembrolizumab is a combination therapy consisting of a novel gut microbiome-derived live biotherapeutic product (MRx0518) and an anti-PD-1 immune checkpoint inhibitor (pembrolizumab). MRx0518 is designed to induce broad immunostimulatory activity to re-engage PD-1 inhibitor activity in patients who have progressed on prior immune checkpoint inhibitors. Preclinical studies showed that MRx0518 increases CD4+ and CD8+ T cell and NK cell infiltration into tumors while decreasing Tregs. The bacterial flagellin moiety activates tumor TLR5, inducing NFκB, cytokine responses, and IFNγ+ CD4+ and CD8+ T cells.

Brand names: MRx0518 + KEYTRUDA

Targets

PDCD1 (Programmed cell death protein 1 receptor)TLR5

Beyond the preview

Go deeper on MRx0518 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRx0518 + pembrolizumab.